Large-scale genome-wide association studies conducted over the last decade have
uncovered numerous genetic variants associated with cardiometabolic traits and risk factors …

Evidence on the validity of drug targets from randomized trials is reliable but typically
expensive and slow to obtain. In contrast, evidence from conventional observational …

Global guidelines for the management of high-cardiovascular-risk patients include
aggressive goals for low-density lipoprotein cholesterol (LDL-C). Statin therapy alone is …

Lowering the levels of LDL cholesterol in the plasma has been shown to reduce the risk of
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …

Background In addition to decreasing the level of cholesterol, proprotein convertase subtilis
kexin 9 (PCSK9) inhibitor has pleiotropic effects, including immune regulation. However, the …

Epidemiologic studies detected an inverse relationship between HDL (high-density
lipoprotein) cholesterol (HDL-C) levels and atherosclerotic cardiovascular disease …

Importance Cholesteryl ester transfer protein inhibition (CETP) has been shown to increase
levels of high-density lipoprotein cholesterol (HDL-C) and reduce levels of low-density …

The development and application of traditional drugs represented by small molecule
chemical drugs and biological agents, especially inhibitors, have become the mainstream …

Abstract Purpose of Review To discuss the history of cardiovascular outcomes trials of
cholesteryl ester transfer protein (CETP) inhibitors and to describe obicetrapib, a next …

Abstract Purpose of the Review High-density lipoproteins (HDL) are responsible for the
transport in plasma of a large fraction of circulating lipids, in part from tissue mobilization …